Fibulin-5 binds urokinase-type plasminogen activator and mediates urokinase-stimulated β1-integrin-dependent cell migration.

Fibulin-5 binds urokinase-type plasminogen activator and mediates urokinase-stimulated β1-integrin-dependent cell migration.

uPA (urokinase-type plasminogen activator) stimulates cell migration through multiple pathways, including formation of plasmin and extracellular metalloproteinases, and binding to the uPAR (uPA receptor; also known as CD87), integrins and LRP1 (low-density lipoprotein receptor-related protein 1) whi...

Full description

Bibliographic Details
Main Authors:	Kapustin, A, Stepanova, V, Aniol, N, Cines, D, Poliakov, A, Yarovoi, S, Lebedeva, T, Wait, R, Ryzhakov, G, Parfyonova, Y, Gursky, Y, Yanagisawa, H, Minashkin, M, Beabealashvilli, R, Vorotnikov, A, Bobik, A, Tkachuk, V
Format:	Journal article
Language:	English
Published:	2012

Similar Items

TISSUE PLASMINOGEN-ACTIVATOR VERSUS UROKINASE
by: Ebers, G
Published: (1988)

The crystal structure of the catalytic domain of human urokinase-type plasminogen activator.
by: Spraggon, G, et al.
Published: (1995)

Urokinase plasminogen activator receptor promotes macrophage infiltration into the vascular wall of ApoE deficient mice.
by: Gu, J, et al.
Published: (2005)

Soluble urokinase plasminogen activator receptor as a prognostic marker in men participating in prostate cancer screening.
by: Kjellman, A, et al.
Published: (2011)

Value of soluble Urokinase plasminogen activator receptor over age as a biomarker of impaired myocardial relaxation
by: Koh, Angela S., et al.
Published: (2018)

Urokinase in the treatment of childhood empyema - Author's reply
by: Thomson, A, et al.
Published: (2003)

Febrile phase soluble urokinase plasminogen activator receptor and olfactomedin 4 as prognostic biomarkers for severe dengue in adults
by: Teo, Andrew, et al.
Published: (2024)

Randomised trial of intrapleural urokinase in the treatment of childhood empyema.
by: Thomson, A, et al.
Published: (2002)

Randomised trial of intrapleural urokinase in the treatment of childhood empyema
by: Thomson, A, et al.
Published: (2000)

Significance of coexpression of urokinase-type plasminogen activator, and matrix metalloproteinase 3 (stromelysin) and 9 (gelatinase B) in colorectal carcinoma.
by: Inuzuka, K, et al.
Published: (2000)

Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy.
by: Steuber, T, et al.
Published: (2007)

Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus
by: Enocsson, H, et al.
Published: (2019)

Production of urokinase by HT 1080 human kidney cell line
by: Roychoudhury, Pradip A., et al.
Published: (1999)

Steady States and Dynamics of Urokinase-Mediated Plasmin Activation In Silico and In Vitro
by: Venkatraman, Lakshmi, et al.
Published: (2014)

Randomised controlled trial of urokinase versus placebo for non-draining malignant pleural effusion
by: Mishra, E, et al.
Published: (2018)

Elevated plasma urokinase receptor predicts low birth weight in maternal malaria.
by: Ostrowski, SR, et al.
Published: (2007)

Selection of acute ischemic stroke patients for intra-arterial thrombolysis with pro-urokinase by using ASPECTS.
by: Hill, MD, et al.
Published: (2003)

Urokinase receptor is necessary for bacterial defense against pneumonia-derived septic melioidosis by facilitating phagocytosis.
by: Wiersinga, W, et al.
Published: (2010)

Phase 1b Trial of LTI-01 (Single Chain Urokinase Plasminogen Activator, scuPA) Intrapleural Fibrinolytic Therapy (IPFT) in Patients with Complicated Parapneumonic Effusions (CPE) or Empyema
by: Idell, S, et al.
Published: (2019)

Phase I trial of the single-chain urokinase intrapleural LTI-01 in complicated parapneumonic effusions or empyema
by: Beckert, L, et al.
Published: (2019)

Enhanced discrimination of benign from malignant prostatic disease by selective measurements of cleaved forms of urokinase receptor in serum.
by: Piironen, T, et al.
Published: (2006)

Intrapleural and plasma processing of LTI-01 (single chain urokinase Plasminogen Activator, scuPA) in a phase 1b trial of LTI-01 Intrapleural Fibrinolytic Therapy (IPFT) in patients with Complicated Parapneumonic Effusions (CPE) or empyema
by: Komissarov, A, et al.
Published: (2019)

Biophysical characterisation of fibulin-5 proteins associated with disease.
by: Schneider, R, et al.
Published: (2010)

Fibulin-3 is necessary to prevent cardiac rupture following myocardial infarction
by: Murtha, LA, et al.
Published: (2023)

An immunohistochemical study of the distribution of plasminogen and plasminogen activators in bullous pemphigoid.
by: Venning, V, et al.
Published: (1993)

Cleavage of Fibulin-2 by the aggrecanases ADAMTS-4 and ADAMTS-5 contributes to the tumorigenic potential of breast cancer cells
by: Fontanil, T, et al.
Published: (2017)

The neurotoxicity of tissue plasminogen activator?
by: Kaur, J, et al.
Published: (2004)

Exposure of plasminogen and the novel plasminogen receptor, Plg-RKT, on activated human and murine platelets
by: Whyte, CS, et al.
Published: (2020)

Tissue Plasminogen Activator and DNase in Empyema REPLY
by: Rahman, N, et al.
Published: (2011)

The different expressions of urokinasetype plasminogen activator, urokinasetype plasminogen activator receptor, and plasminogen activator inhibitor-1. Several scores of cell pleomorphism, number of mitosis and keratiniza
by: Perpustakaan UGM, i-lib
Published: (2008)

Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects
by: Al-Hamodi, Z., et al.
Published: (2011)

Effect of plasminogen activator inhibitor-1 and tissue plasminogen activator polymorphisms on susceptibility to type 2 diabetes in malaysian subjects
by: Al-Hamodi, Z., et al.
Published: (2012)

Stroke thrombolysis: is tissue plasminogen activator a defibrillator for the brain?
by: Buchan, A, et al.
Published: (2000)

Do plasminogen activators play a role in lichen sclerosus?
by: Farrell, A, et al.
Published: (2000)

Intrapleural use of tissue plasminogen activator and DNase in pleural infection
by: Rahman, N, et al.
Published: (2011)

Intrapleural use of tissue plasminogen activator and DNase in pleural infection.
by: Rahman, N, et al.
Published: (2011)

Responsiveness of choroidal neovascular membranes in patients with R345W mutation in fibulin 3 (Doyne honeycomb retinal dystrophy) to anti-vascular endothelial growth factor therapy.
by: Sohn, E, et al.
Published: (2011)

Defining the structural basis of human plasminogen binding by streptococcal surface enolase.
by: Cork, A, et al.
Published: (2009)

Complications associated with recombinant tissue plasminogen activator therapy for acute ischaemic stroke.
by: Balami, J, et al.
Published: (2013)

Effectiveness of tissue-type plasminogen activator for acute ischemic stroke: Consequences of protocol violation
by: Karbalai, H, et al.
Published: (1999)